Welcome to the Carolina BioOncology Institute (CBI). We are a cancer therapy and research institute. Our staff are dedicated to advancing the field of cancer research by making available the latest developments in therapeutic options. CBI has developed an early phase clinical trial program which represents the cutting edge in immunotherapy and personalized cancer options. Additionally, CBI is the incubator for BioCytics, a research and development firm working to identify novel drug targets. We are excited that you are considering a visit to our clinic and we look forward to providing you with the most recent clinical trial options and the highest quality care.
Recent Clincial Trials
Protocol INCB24360-203 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Protocol D4191C00011 (AZ11) A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) with a Sequential Switch to a 2nd IMT (MEDI4736) in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV)
Protocol MGA271: A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3
Protocol CP-MGD007-01: A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma.
Protocol CD-ON-MEDI4736-1108: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 (anti-PD-L1) in Subjects with Advanced Solid Tumors
Protocol D4981C00001: A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 (OX40 agonist) in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Protocol D4191C00003: A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736 (anti-PD-L1) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen
Protocol EMR 100070-001: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of an anti-PD-L1 antibody in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Protocol GO28754: A Phase II, Multicenter, Single-Arm Study of MPDL3280A (anti-PD-L1) in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Protocol GP28328: A Phase IB Study of the Safety and Pharmacology of MPDL3280A (anti-PD-L1) Administered with Bevacizumab and/or Chemotherapy in Patients with Advanced Solid Tumors
Protocol PCD4989g: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A (anti-PD-L1) Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors of Hematologic Malignancies
A couple of recent articles have been published that feature the results of the Phase I clinical trials run at Carolina BioOncology. In November of 2014, Dr. Powderly was part of the team that authored the letter to Nature entitled “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients”. This paper discusses […]
Dr. Powderly is participating in two upcoming cancer meetings. On April 23 and 24th, he will attend the Community Oncology Conference in Orlando, Florida. At this meeting, Dr. Powderly will speak about PD1 and PDL-1, how their interaction plays a role in cancer growth and how the latest immuno-oncology drugs are designed to interrupt the […]